Search for Clinical Trial Results

Sponsored By

Light Chain Deposition Disease - 10 Studies Found

Status Study
Active, not recruiting Study Name: Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
Condition:
  • Primary Systemic Amyloidosis
  • Light Chain Deposition Disease Date: 2007-08-24
    Interventions:
    • Drug: bortezomib Bortezomib 1.
Suspended Study Name: First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD
Condition:
  • Light Chain Deposition Disease
  • Primary Systemic Amyloidosis Date: 2012-11-13
    Interventions:
    • Drug: pomalidomide Given PO
Active, not recruiting Study Name: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
Condition: Multiple Myeloma
Date: 2009-11-16
Interventions: Device: Administering three additional MRI images Three additional MRI images to determine the role of c
Completed Study Name: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition:
  • Light Chain Deposition Disease
  • Refractory Plasma Cell Myeloma Date: 2012-02-11
    Interventions:
    • Other: Diagnostic Laboratory Biomarker Analysis

Recruiting Study Name: Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Condition:
  • Light Chain Deposition Disease
  • Smoldering Plasma Cell Myeloma Date: 2010-07-23
    Interventions:
    • Other: Clinical Observation Un
Completed Study Name: Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis
Condition:
  • Light Chain Deposition Disease
  • Primary Systemic Amyloidosis Date: 2010-02-27
    Interventions:
    • Drug: melphalan Given PO
Terminated Study Name: HD Melphalan and SCT in Patients With IGDD or LCDD
Condition: Multiple Myeloma
Date: 2008-05-18
Interventions:
  • Biological: filgrastim 16 mcg/
Active, not recruiting Study Name: Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Condition:
  • Light Chain Deposition Disease (LCDD or MIDD)
  • Light Chain and H
    Date: 2011-06-27
    Interventions: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Recruiting Study Name: Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Condition:
  • Extramedullary Plasmacytoma
  • Isolated Plasmacytoma of Bone

  • Date: 2013-05-06
    Interventions:
    • Drug: dexamethasone Given PO
Completed Study Name: Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Condition:
  • Accelerated Phase Chronic Myelogenous Leukemia
  • Acute Myeloid Leukemia With Multilineage Dysp
    Date: 2009-04-29
    Interventions:
    • Drug: sunitinib malate Given P